Core Viewpoint - Sichuan Huiyu Pharmaceutical Co., Ltd. announced a cash dividend of 0.4632 RMB per share for the fiscal year 2024, approved at the annual shareholders' meeting on May 16, 2025 [1][5]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 4.632 RMB for every 10 shares held, with no capital reserve fund conversion or bonus shares issued [3][4]. - The total number of shares eligible for distribution is 421,460,122 after excluding 2,139,878 shares held in the company's repurchase account, leading to a total cash dividend payout of approximately 195.22 million RMB [3][6]. Shareholder Eligibility - All shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the equity registration date are eligible for the dividend [2]. Taxation Details - Individual shareholders holding shares for over one year are exempt from personal income tax on dividends, while those holding for less than one year will have taxes deducted upon stock transfer [10][11]. - The actual cash dividend received by shareholders with different holding periods varies, with a tax rate of 20% applied for those holding shares for less than one month [11][12]. Implementation Method - The dividends will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited, with specific arrangements for shareholders who have not completed designated trading [7][9].

上海东方华银律师事务所 关于四川汇宇制药股份有限公司 差异化分红事项 之 法律意见书 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 68769686 传真：(8621) 58304009 上海东方华银律师事务所 关于四川汇宇制药股份有限公司 本所律师依据本法律意见书出具日以前已经发生或存在的事实并基于对现 行法律、法规和规范性文件的理解发表法律意见。对于出具本法律意见书至关重 要而又无法得到独立的证据支持的事实，本所律师依赖公司或者其他有关机构出 具的证明文件。 本法律意见书仅就本次差异化分红所涉及的法律问题发表法律意见，并不对 有关会计、审计等专业事项和报告发表意见。本法律意见书若对有关审计报告中 2 某些数据和结论的引述，并不意味着本所对这些数据、结论的真实性和准确性做 出任何明示或默示的保证。对于该等数据、报告的内容，本所以及本所律师并不 具备核查和作出评价的适当资格。 差异化分红事项 之法律意见书 致：四川汇宇制药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上海证券交易所交易规则》、《上市公司股份 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-046 四川汇宇制药股份有限公司 2024年年度权益分派实施公告 一、 通过分配方案的股东大会届次和日期 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 及其他规范性文件和《公司章程》的有关规定，公司回购专用证券账户中的股份 是否涉及差异化分红送转：是 每股分配比例 重要内容提示： 每股现金红利0.4632元 相关日期 | | 股权登记日 | | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | 2025/6/12 | ...

Core Viewpoint - The financial performance of Huiyu Pharmaceutical shows a significant increase in revenue and net profit, but the underlying growth is driven by non-recurring gains, indicating potential fragility in its financial health [2]. Group 1: Financial Performance - Huiyu Pharmaceutical reported a revenue of 1.09 billion yuan, representing a year-on-year increase of 18.05%, and a net profit of 325 million yuan, up 132.78% [2]. - After excluding non-recurring gains, the net profit was only 92 million yuan, reflecting a more modest year-on-year growth of 39.55% [2]. - The core profit driver was the fair value changes of financial assets, particularly a gain of 211 million yuan from the investment in a drug company, which constituted 64.9% of the net profit [2]. Group 2: International Expansion - The overseas business has become a significant growth engine, with foreign sales revenue reaching 166 million yuan, a year-on-year increase of 97.12% [3]. - The company obtained 101 new drug approvals, expanding its market coverage from 54 to 68 countries [3]. - However, overseas revenue only accounts for 15.2% of total revenue, and the reliance on low-margin generic drug exports poses challenges, including rising costs for EU GMP certification and currency fluctuations in emerging markets [3]. Group 3: Domestic Strategy - The domestic business has improved structurally through a strategy focused on high-barrier generics and first-to-market products, resulting in 17 new generic drug launches [4]. - Domestic sales revenue grew by 10.12% to 928 million yuan, supported by stable cash flow from 10 products that won national or provincial procurement bids [4]. - Despite this growth, the average annual price decline for generics exceeds 50% due to normalized bulk purchasing, raising questions about the sustainability of revenue growth [4].

证券代码：688553 证券简称：汇宇制药 公告编号：2025-045 二、药品的其他相关情况 硫酸多黏菌素 B 几乎对除奇异变形杆菌外所有革兰阴性菌有杀菌作用。多 黏菌素通过改变细菌细胞膜通透性导致细菌死亡。革兰阳性菌、真菌、革兰阴性 球菌对多黏菌素耐药。注射用硫酸多黏菌素 B 用于治疗碳青霉烯类耐药革兰氏 阴性杆菌引起的严重感染的成年患者，包括铜绿假单胞菌敏感菌株引起的脑膜炎 和菌血症。 四川汇宇制药股份有限公司 自愿披露注射用硫酸多黏菌素 B 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇宇海玥 医药科技有限公司于近日收到国家药品监督管理局核准签发的公司产品注射用 硫酸多黏菌素 B 的《药品注册证书》，现将相关情况公告如下： | 药品名称 | 注射用硫酸多黏菌素 B | | --- | --- | | 剂型 注射剂 | | | 规格 | 50万单位 | | 注册分类 | 化学药品3类 | | 药品有效期 24个月 | | | 上市许 ...

Core Viewpoint - The company has received approval for the injectable colistin sulfate from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., has been granted a drug registration certificate for injectable colistin sulfate [1] - Injectable colistin sulfate is classified as a Class 3 chemical drug with a specification of 500,000 units and a shelf life of 24 months [1] Group 2: Market Potential - The drug is intended for treating severe infections in adult patients caused by carbapenem-resistant Gram-negative bacteria, including meningitis and bacteremia caused by sensitive strains of Pseudomonas aeruginosa [1] - The projected sales revenue for injectable colistin sulfate in urban public hospitals in China for 2024 is estimated to be 529 million yuan [1] Group 3: Future Outlook - The company has initiated preparatory work for the product's market launch, but there is uncertainty regarding its potential to generate significant revenue in the future [1]

Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]

Group 1 - The core viewpoint of the news highlights the significant performance of the innovative drug sector, with the Tianhong Innovative Drug ETF (517380) showing a nearly 20% increase year-to-date as of May 29, 2023 [1] - The Tianhong Innovative Drug ETF, launched in 2021, tracks the "Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - On May 29, the National Medical Products Administration approved 11 new drugs, with five being from innovative companies listed on the Sci-Tech Innovation Board, covering various therapeutic areas including oncology and autoimmune diseases [1] Group 2 - The upcoming 2025 ASCO Annual Meeting in Chicago is expected to showcase significant data from domestic innovative drug companies, with 71 original research results from Chinese pharmaceutical companies selected for presentation [2] - The innovative drug sector is anticipated to gain increased attention and positive market sentiment, with institutional holdings currently at low levels and the sector's valuation significantly below historical averages [2] - The total amount of outbound transactions for innovative drugs has reached $45.5 billion since the beginning of 2025, indicating a strong trend towards internationalization and potential for future growth [3] Group 3 - The Chinese innovative drug industry has transitioned from imitation to rapid following and now to original innovation, marking a significant evolution in its development [3] - Most domestic innovative drugs currently in the U.S. are in clinical stages, with future milestones expected to validate the growth and internationalization of Chinese innovative drugs [3]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-044 二、药品的其他相关情况 注射用环磷酰胺是一种肿瘤药，主要用于治疗慢性淋巴细胞白血病（CLL）； 急性淋巴细胞白血病（ALL）；作为骨髓移植的条件，联合全身照射或白消安治 疗急性淋巴细胞白血病、慢性淋巴细胞白血病和急性髓系白血病；霍奇金淋巴瘤、 非霍奇金淋巴瘤和多发性骨髓瘤；转移性卵巢癌和乳腺癌；乳腺癌的辅助治疗； 尤文氏肉瘤；小细胞肺癌；晚期或转移性神经母细胞瘤；危及生命的自身免疫性 疾病：严重进行性狼疮肾炎和韦格纳肉芽肿病。 公司注射用环磷酰胺研发成功后已进行了多国注册申报，分别已在中国、英 国、爱尔兰、葡萄牙、法国、荷兰、意大利、西班牙获得上市许可。截至目前， 公司已在德国提交注册申请。 三、对公司的影响及风险提示 公司研发的注射用环磷酰胺获得英国的上市许可，有利于公司在国际市场产 品管线的丰富，提升市场的品牌形象，持续拓展国际业务的广度和深度，为国际 序 号 产品名称 剂型 规格 上市许可号 发证国家 1 注射用环磷酰胺 注射剂 500mg； 1000mg； 2000mg； PL 41013/0079 PL 41013/0080 P ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-041 四川汇宇制药股份有限公司 监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司"或"汇宇制药"）第二届监 事会第十五次会议于 2025 年 5 月 24 日以电子邮件方式发出通知，并于 2025 年 5 月 29 日以通讯表决方式召开。本次会议由公司监事会主席邓玲女士召集并主 持，应出席监事 3 人，实际出席监事 3 人。全体监事认可本次会议的通知时间、 议案内容等事项，本次监事会的召集和召开程序符合《中华人民共和国公司法》 《中华人民共和国证券法》等法律法规及《公司章程》的相关规定，会议决议合 法有效。 二、监事会会议审议情况 1、审议通过《关于部分募投项目节余募集资金永久补充流动资金的议案》 监事会认为：本次部分募投项目节余募集资金永久补充流动资金符合《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所科创板股票上市规则》《上海证券交 ...